Logo

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study

Author(s):
Maissa El RazikyMaissa El Raziky1, Waleed Fouad FathalahWaleed Fouad Fathalah1,*, Wafaa Ahmed El-akelWafaa Ahmed El-akel1, Ahmed SalamaAhmed Salama1, Gamal EsmatGamal Esmat1, Mahassen MabroukMahassen Mabrouk1, Rabab Mamoun SalamaRabab Mamoun Salama1, Hany Mahmoud KhatabHany Mahmoud Khatab2
1Department of Endemic Medicine and Hepatology, Cairo University, Cairo, Egypt
2Department of Pathology, Cairo University, Cairo, Egypt


Hepatitis Monthly:Vol. 13, issue 5; 10069
Published online:May 27, 2013
Article type:Research Article
Received:Jan 01, 2013
Accepted:Apr 16, 2013
How to Cite:Maissa El RazikyWaleed Fouad FathalahWafaa Ahmed El-akelAhmed SalamaGamal EsmatMahassen MabroukRabab Mamoun SalamaHany Mahmoud Khatabet al.The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study.Hepat Mon.13(5):10069.https://doi.org/10.5812/hepatmon.10069.

Abstract

Background:

Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naive HCV-infected patients have shown conflicting results.

Objectives:

assessing the effects of Peginterferon alpha-2a versus Peginterferon alpha-2b on the sustained virological response in naive chronic HCV genotype-4 Egyptian patients.

Patients and Methods:

this retrospective study cohort consists of 3718 chronic HCV patients admitted to a large, Egyptian medical center. 1985 patients had been treated with PEG-IFN alfa-2a plus RBV and 1733 patients with PEG-IFN alfa-2b plus RBV between years 2007-2011. Efficacy outcomes were sustained virologic response (SVR) and treatment discontinuation rates due to serious adverse effects.

Results:

The ETR & SVR in patients treated with PEGIFN alfa-2a was 64.1% and 59.6% as compared to treatment with PEGIFN alfa-2b where these parameters were 58.2% and 53.9% respectively (P < 0.05). Treatment discontinuation rates, were similar in the two types of PEGIFN [0.66 (0.37-1.16); P = 0.15]. Significant dose reduction was evident with peginterferon alfa-2b (35.3%) than peginterferon alpha-2a (27.3 %) (P < 0.01). Patients with lower base line AFP and ALT were most likely to achieve SVR using INF alpha 2-a.

Conclusions:

Peginterferon alpha-2a has a higher efficacy regarding ETR and SVR as compared to Peginterferon alfa-2b in treatment of naive chronic HCV genotype-4 patients.

Full Text

Full text is available in PDF

comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles